Welcome to our dedicated news page for Opthea American Depositary Shares (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea American Depositary Shares.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Opthea American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Opthea American Depositary Shares's position in the market.
Rhea-AI Summary
Opthea Limited announced the appointment of Dr. Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development, and Dr. Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs. Both bring extensive experience in products for retinal and ophthalmology diseases. Dr. Clark and Dr. Li will report to Opthea CEO Frederic Guerard and will join the Opthea Executive Management Team. The company is preparing for the next stage in its growth and working towards advancing the development of sozinibercept (OPT-302), currently in two Phase 3 pivotal trials. Dr. Clark and Dr. Li expressed excitement to contribute to the potential success of the lead program investigating sozinibercept and to bring this novel product candidate to patients with serious retinal disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
-
Rhea-AI Summary
Opthea Limited (ASX:OPT; NASDAQ:OPT) to receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and Abingworth, as well as a further US$50m financing under an Amended DFA to include a new co-investor. The financing is non-dilutive to shareholders, with no equity issued to Carlyle, Abingworth, or the new co-investor. This investment is driven by the potential of sozinibercept (OPT-302) to provide superior visual outcomes for wet AMD patients and to provide a multi-billion dollar commercial opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.65%
Tags
-
Rhea-AI Summary
Opthea Limited (ASX:OPT; Nasdaq:OPT) has received an A$8.8 million (US$5.9 million) research and development (R&D) tax credit from the Australian Taxation Office for the 2022/2023 financial year. The cash incentive is for the development of Opthea’s lead candidate OPT-302, strengthening the company’s cash position as it advances its Phase 3 registrational trials for wet AMD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
Rhea-AI Summary
Opthea Limited (ASX:OPT; NASDAQ:OPT) announced an oral presentation featuring sozinibercept (OPT-302) at the FLORetina Congress. The presentation will focus on sozinibercept combination therapy in neovascular age-related macular degeneration (nAMD), a highly prevalent and progressive retinal disease. The annual FLORetina Congress is one of the largest retina meetings in Europe with over 2500 participants attending from over 50 countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
-
Rhea-AI Summary
Opthea Limited (NASDAQ:OPT; ASX:OPT) announced that Dr. Megan Baldwin, the Company’s Founder and Chief Innovation Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference. The chat will occur on November 15th at 12:20PM – 12:55 PM GMT and can be accessed live by registering at the provided link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
-
Rhea-AI Summary
Opthea Limited announced that Dr. Megan Baldwin, the Company’s Founder & Chief Innovation Officer, will present at Eyecelerator as part of AAO 2023. The event aims to connect entrepreneurs, investors, companies, and physicians to advance ophthalmic innovation. The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
Rhea-AI Summary
Opthea Limited announces leadership changes with Dr. Megan Baldwin transitioning to Founder and Chief Innovation Officer, and the appointments of Dr. Frederic Guerard as CEO and Peter Lang as CFO. Opthea aims to advance its US and global presence and commercialization strategy for sozinibercept (OPT-302).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
-
Rhea-AI Summary
Opthea Limited's CEO, Dr. Megan Baldwin, will be a panelist at the Euretina Innovation Spotlight forum on October 4th, showcasing the company's retinal disease therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
-
Rhea-AI Summary
Opthea CFO to present at H.C. Wainwright's conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
Rhea-AI Summary
Opthea successfully completes capital raising, raising approximately A$73.7m through placement and institutional entitlement offer. Additional A$10.0 million in oversubscriptions accepted, increasing total capital raising to A$90.0 million. Retail entitlement offer to raise approximately A$16.3m to open on August 31, 2023. Proceeds will be used for clinical development of OPT-302 for wet AMD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.74%
Tags
Opthea Limited American Depositary Shares
Nasdaq:OPT
OPT Rankings
OPT Stock Data
272.17M
480.83M
9.46%
0.15%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
Melbourne
About OPT
opthea limited (formerly circadian technologies) is a public australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. opthea's lead compound, opt-302, blocks two members of the vascular endothelial growth factor family, namely vegf-c and vegf-d, which cause blood vessels to grow and leak. aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet amd). opthea is currently investigating opt-302 in an ongoing phase 1/2a clinical trial in wet amd patients. enquiries can be directed to: info@opthea.com